During the last two decades, there have been impresallograft recipients transplanted in recent years. sive improvements in the control of immunologic events Background. Post-transplant diabetes mellitus (PTDM) is a that follow renal transplantation. Consequently, the numserious complication of transplantation caused by immunosupber of acute rejection episodes early post-transplant has pressive drugs. In this study, we assessed the incidence of PTDM declined dramatically and graft survival, particularly durand the factors that are associated with the development of this complication. ing the first year post-transplant, has improved substan-Methods. The study population included 2078 non-DM renal tially [1, 2]. It is clear that in large part, these improvements allograft recipients, transplanted since 1983 in one institution.
cant improvements in graft survival [3] . However, high Cox, the following variables correlated with a more rapid inpatient mortality continues to be the major threat to the crease in the number of PTDM cases: (1) older age (RR ϭ success of renal transplantation [4, 5] . Because the excess 2.2 comparing patients younger or older than 45 years, P Ͻ 0.0001), (2) transplant done after 1995 (RR ϭ 1.7, P ϭ 0.003), mortality of transplant recipients is largely due to cardio-(3) African American race (RR ϭ 1.6, P ϭ 0.003), and (4) vascular causes [6] , searching for variables associated higher body weight at transplant (RR ϭ 1.4, P Ͻ 0.0001).
with increased cardiovascular risk and correcting those Compared with before 1995, since 1995, the percentage of variables are critically important. Previous studies have patients with PTDM has increased from 5.9 to 10.5% at one identified several cardiovascular risk factors in patients year and from 8.8 to 16 .9% at three years. This increase was statistically independent from all other variables tested. Howwith end-stage renal disease and in transplant patients ever, since 1995, recipients have become significantly heavier [7, 8] . However, it has also been pointed out that the (P Ͻ 0.0001) and older (P Ͻ 0.0001), and the average CsA cardiovascular mortality of patients with kidney disease level has increased significantly (P Ͻ 0.0001). Also, since 1995, is much higher than that of patients without kidney probthe cumulative dose of corticosteroids has declined (P Ͻ lems who have a similar risk profile [9]. These results 0.0001); patients received a newer, better absorbed preparation of CsA and received mycophenolate mofetil.
suggest that other cardiovascular risk factors need to be Conclusions. The risk of PTDM increases continuously with considered in patients with kidney disease. One of those time post-transplant. There has been an increase in the incidence factors is likely to be insulin resistance that occurs comof PTDM in patients transplanted recently, and that increase monly in patients receiving immunosuppressive medicacan be explained only partially by changes in the recipients' tions and is clearly associated with increased cardiovascharacteristics. We postulate that this increase may be due to the introduction of better absorbed CsA formulations that cular risk [10, 11] . result in higher blood levels and higher cumulative exposure
The ultimate manifestation of insulin resistance in transto this diabetogenic drug. plant patients is the development of post-transplant diabetes mellitus (PTDM). The issue of PTDM has been recently reviewed in the literature [12] . However, impor- sessed the timing of the development of DM after transplantation, the influence of different variables on that timing, and whether the introduction of newer immunosuppressive medications has had effects on the overall incidence of PTDM and its pattern of presentation. The latter is an important consideration because in addition to corticosteroids, newer immunosuppressive medications, which have clearly contributed significantly to improve- 12]. It is our hope that a better characterization of PTDM, first on clinical grounds, will facilitate its early detection and treatment as well as help in the design of future trials patients, of triple therapy with prednisone, azathioprine, to prevent the development of this devastating complicamaintenance immunosuppression consisted and cyclotion of transplantation. sporine (CsA) until the mid-1995 when azathioprine was replaced by mycophenolate mofetil (CellCept) and Sand-METHODS immune was substituted for Neoral. Based on these Patient population changes in immunosuppressive protocols, patients were divided by the date of transplantation into those trans-This study includes an analysis of 2078 patients transplanted prior to July 1, 1995 (N ϭ 1551), and those planted in a single institution from August of 1982 to transplanted after that date (N ϭ 527). February of 1999. This population included 606 patients who received kidneys from living donors (LRDs) and
Analysis of the data 1464 patients who received kidneys from cadaveric do-
The data are expressed as means Ϯ SD. Means were nors (CADs). The demographic characteristics of the compared by Student t test or by the nonparametric patient populations are shown in Table 1 . None of these test if the variable was not normally distributed. The patients had a history of DM prior to transplantation. In incidence of PTDM over time post-transplant was anaaddition, all of the patients who required hypoglycemic lyzed by Cox regression (univariate and multivariate) medications during the first month post-transplant were and also by Kaplan-Meier plots after censoring patients not included in this cohort of patients because it was for patient death and for graft loss. considered that these patient most likely were diabetic prior to transplantation. No precise information about the recipients' family histories of DM was available; thus, RESULTS this variable was not considered in these studies. The
Incidence of PTDM diagnosis of PTDM was made when the patient started Figure 1 displays the cumulative incidence of PTDM to require hypoglycemic medications, including either with time post-transplant. During the first six-months oral hypoglycemic drugs and/or insulin. post-transplant, 5.9% of patients developed this compli-All CAD kidneys were preserved by pulsatile perfucation. Thereafter, the percentage of cases of PTDM insion. In the immediate post-transplant period, patients creased linearly with time post-transplant. The cumulareceived induction immunosuppression consisting of polytive percentage of PTDM at 1, 3, 5, 10, and 15 years was clonal (Minnesota ALG or ATG) or monoclonal anti-7.1, 10.4, 13.2, 20.5, and 29.8%, respectively. lymphocyte antibodies (OKT3; Ortho Biotech, Raritan, Table 2 displays the results of univariate and multivari-NJ, USA) until the serum creatinine was Յ2.5 mg/dL ate Cox regression analysis and shows the variables that when CsA was initiated. Since May of 1998, induction correlate significantly with the development of PTDM. has been done with two doses of anti-interleukin-2 (IL-2) Statistically, the strongest correlation found was between receptor monoclonal antibodies (Basilxilimub, Simulect, Novartis) instead of antilymphocyte antibodies. In most the age of the patient at the time of transplantation and DM after transplantation. The number of non-Caucasian, non-African American recipients is very small in our patient population (1.6%); thus, these patients could not be analyzed separately. The only statistically significant difference noted between African American and Caucasian recipients was in the recipients' weights, which were higher in the former than in the latter group (77.5 Ϯ 20 vs. 74 Ϯ 18 kg, P ϭ 0.01). This difference is relevant because the weight of the recipient at the time of transplantation also correlated significantly with the develop- PTDM increases significantly with increasing weight at the time of transplantation in both Caucasians and African Americans. However, for each weight group, the inci-PTDM. Thus, recipients older than 45 years old were dence of PTDM was higher in African Americans than 2.9 times more likely to become diabetic post-transplant in Caucasians. than younger recipients. Figure 2 displays Kaplan-Meier Table 2 also shows that the incidence of PTDM was plots of the proportion of patients with PTDM in recipisignificantly higher in males than in females (15.2 vs. ents who were younger than 45 or more than 45 years 10.4%, P ϭ 0.002 by chi square). However, by multivariate old at the time of transplantation. As can be seen, the analysis, the recipient's gender was not an independent risk of PTDM is significantly higher in older recipients risk factor for diabetes. Similarly, PTDM developed more both during the six months post-transplant and beyond.
commonly after CAD kidney transplantation (14.5%) It should be noted in Figure 2 that the rate of increase than in recipients of LRD (10.4%, P ϭ 0.01), but the in PTDM cases after the first six months is significantly multivariate analysis indicates that the origin of the dofaster in older than in younger individuals. As demonnor graft is not an independent predictor of PTDM. strated in Table 2 , the relationship between PTDM and Other donor variables, including age, race, and gender the age of the recipient is statistically independent from did not correlate with the incidence of PTDM. Of interall other variables tested.
est, the incidence of PTDM did not correlate significantly Race is also an independent predictor of PTDM (Tawith the amount of weight gain that the patient had ble 2). Thus, 18% of African American recipients and 12% of Caucasians (P ϭ 0.01 by chi square) developed during the first year post-transplant. 
PTDM versus transplantation year
The incidence of PTDM was 1.9 times higher in patients transplanted since 1995 compared with those transplanted prior to that year (Table 2) . Furthermore, the July of 1995, the recipient population became signifimultivariate analysis shows that this correlation is statiscantly older and heavier. However, Figure 5 re-emphatically independent from all other variables tested.
sizes that the correlation between the date of trans-Kaplan-Meier curves of PTDM in recipients transplantation and PTDM is statistically independent from planted prior to and after 1995 are displayed in Figure the age and/or weight of the recipient. Thus, it can be 4. As can be seen, since July of 1995, the risk of PTDM seen that the incidence of PTDM is significantly higher has increased both during the first six-months post-transin obese recipients (Fig. 5, top) and in recipients older plant and beyond, with a significantly faster rate of inthan 45 years old (Fig. 5, bottom) transplanted after 1995 crease in the number of PTDM cases. Thus, at one and than before that year. It should also be noted in Table three years, the incidences of PTDM were 6 and 8.7%
3 that significant changes in immunosuppression have in patients transplanted before 1995 and 10.6 and 17.1% also occurred since 1995. Thus, the cumulative dose of corticosteroid received by patients transplanted after in those transplanted since 1995.
It is likely that several factors contributed to the in-July of 1995 was significantly lower than prior to that date. This reduction is not the result of a protocol change creased occurrence of PTDM since 1995. For example, Table 3 displays a comparison between the patient char-but the result of the significant decrease in the number of acute rejection episodes during the first year post-acteristics prior to and after 1995. As can be seen, after transplant (before 1995, 1 Ϯ 1.4 episodes per patient vs. studies showed that abnormalities in insulin/glucose metabolism are racially diverse [16] . Thus, it is likely that after 1995, 0.5 Ϯ 0.5, P Ͻ 0.0001 by Wilcoxon). The cumulative dose of CsA has not changed significantly the mechanisms of PTDM in individuals of different racial groups may also be different. since 1995 (Table 3) . However, the average CsA level during the first year post-transplant was significantly
We showed here that weight is a risk factor for PTDM and that African American recipients are significantly higher in patients transplanted after 1995 than in those transplanted before that date, most likely reflecting the heavier than Caucasians. However, we showed that for patients with similar body weights, the risk of PTDM is use of better absorbed formulations of CsA.
still higher in African Americans. It should be emphasized that in renal transplant recipients, the risk of PTDM DISCUSSION increases continuously for every increment of body In the present study, we evaluated the incidence of weights above 60 kg, clearly below what may be consid-PTDM in a large group of renal allograft recipients, ered to be an overweight range for most patients. Weight transplanted in a single institution, and treated with unigain is a very common problem post-transplantation. form CsA-based immunosuppressive protocols. The inci-However, in this study, we did not find a significant dence of PTDM reported here is similar to that noted correlation between weight gain during the first year in other studies. However, there is a significant variability post-transplant and PTDM but rather between pretransin the reported incidence of PTDM, most likely because plant weight and PTDM. of at least three reasons. First, the criteria used to diag-For all racial and weight groups and for both patients nose PTDM are quite variable among studies [12] . Sectransplanted in the remote past or more recently, the age ond, variability in the immunosuppressive protocols used of the recipient at the time of transplantation is statistiin different transplant centers will have an impact in cally the strongest predictor of the risk for PTDM. The the incidence of PTDM. For example, the incidence of increased risk of PTDM in older recipients has two dis-PTDM is significantly higher in transplant recipients tinct components. First, compared with younger recipitreated with tacrolimus than in those treated with CsA ents, patients older than 45 years have a marked increase [13] . Finally, the reported incidence of PTDM will vary in the incidence of PTDM during the first six months according to the length of patient follow-up because, post-transplant when the patient is receiving the highest as shown here, the percentage of patients who develop doses of corticosteroids. Second, beyond six months PTDM increases continuously post-transplant. Regardpost-transplant, the rate of increase in the number of ing this latter point, these results showed that there are cases of PTDM is faster in older than in younger individtwo distinct periods of PTDM development. The first, a uals. It seems reasonable to postulate that PTDM may period of high risk, comprises the first six-months postcomprise at least two subpopulations of individuals. The transplant. The second comprises the rest of the postfirst, including patients who develop diabetes early posttransplant time when there is a continuous increase in transplant, most likely represents patients who had insuthe number of patients with PTDM. In this study, we lin resistance prior to the transplant that was made worse diagnosed PTDM as the need for hypoglycemic medicaby high doses of steroids, requiring the initiation of hypotions. Thus, the incidence of PTDM reported here, alglycemic therapy. The second group of patients who though high, is likely to be an underestimate of the true develop PTDM beyond six months post-transplant and magnitude of the problem. This is particularly relevant may represent newly acquired diabetic individuals, either when we consider that the incidence of PTDM has inwith hyperinsulinemia and insulin resistance or with hycreased rather sharply since 1995.
poinsulinemia [12] . The results of this analysis showed that the risk of For the first time, we showed here that the incidence PTDM is higher in African American recipients than of PTDM has increased rather sharply since 1995 to the in Caucasian recipients. This finding is consistent with present time. In fact, the number of PTDM cases has previous observations in transplant recipients [12] and nearly doubled since 1995, and the linear shape of the also with the observation that, in the general population, Kaplan-Meier plots suggests that more than 40% of rethe incidence of type II DM is significantly higher in cipients transplanted since 1995 may acquire DM within African Americans than in Caucasians [14, 15] . Furtherfive-years post-transplant. These results suggest that more, among nondiabetic subjects, the incidence of hythe increase in PTDM is multifactorial, including both perinsulinemia and insulin resistance is also higher in changes in patients' risk profiles and changes in immuno-African Americans than in Caucasians [15] . Thus, it is suppressive medications. Thus, since 1995, renal translikely that more African Americans than Caucasians plant recipients in our institution have become signifihave insulin resistance prior to transplantation, and in cantly heavier and significantly older. However, the these patients, treatment with immunosuppressive drugs increased incidence of PTDM since 1995 is statistically independent from these two factors. We postulate that that are diabetogenic would result in PTDM. Previous
